[go: up one dir, main page]

EP3004870A4 - Diagnostic différentiel de tumeurs bénignes - Google Patents

Diagnostic différentiel de tumeurs bénignes Download PDF

Info

Publication number
EP3004870A4
EP3004870A4 EP13885931.9A EP13885931A EP3004870A4 EP 3004870 A4 EP3004870 A4 EP 3004870A4 EP 13885931 A EP13885931 A EP 13885931A EP 3004870 A4 EP3004870 A4 EP 3004870A4
Authority
EP
European Patent Office
Prior art keywords
differential diagnosis
benign tumors
benign
tumors
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13885931.9A
Other languages
German (de)
English (en)
Other versions
EP3004870A1 (fr
EP3004870B1 (fr
Inventor
Joseph Kapelushnik
Shaul Mordechai
Ilana Nathan
Udi Zelig
Rami Zigdon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Todos Medical Ltd
Original Assignee
Todos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Todos Medical Ltd filed Critical Todos Medical Ltd
Priority to EP18214760.3A priority Critical patent/EP3489659B1/fr
Publication of EP3004870A1 publication Critical patent/EP3004870A1/fr
Publication of EP3004870A4 publication Critical patent/EP3004870A4/fr
Application granted granted Critical
Publication of EP3004870B1 publication Critical patent/EP3004870B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/3563—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/3577—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N2021/3595—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using FTIR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/12—Circuits of general importance; Signal processing

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
EP13885931.9A 2013-05-28 2013-11-14 Diagnostic différentiel de tumeurs bénignes Not-in-force EP3004870B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18214760.3A EP3489659B1 (fr) 2013-05-28 2013-11-14 Procédé pour indiquer la présence de tumeurs bénignes à l'aide d'un échantillon de cellules mononucléaires périphériques (pbmc)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827933P 2013-05-28 2013-05-28
PCT/IL2013/050945 WO2014191980A1 (fr) 2013-05-28 2013-11-14 Diagnostic différentiel de tumeurs bénignes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP18214760.3A Division EP3489659B1 (fr) 2013-05-28 2013-11-14 Procédé pour indiquer la présence de tumeurs bénignes à l'aide d'un échantillon de cellules mononucléaires périphériques (pbmc)

Publications (3)

Publication Number Publication Date
EP3004870A1 EP3004870A1 (fr) 2016-04-13
EP3004870A4 true EP3004870A4 (fr) 2017-03-01
EP3004870B1 EP3004870B1 (fr) 2019-01-02

Family

ID=51988105

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13885931.9A Not-in-force EP3004870B1 (fr) 2013-05-28 2013-11-14 Diagnostic différentiel de tumeurs bénignes
EP18214760.3A Not-in-force EP3489659B1 (fr) 2013-05-28 2013-11-14 Procédé pour indiquer la présence de tumeurs bénignes à l'aide d'un échantillon de cellules mononucléaires périphériques (pbmc)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18214760.3A Not-in-force EP3489659B1 (fr) 2013-05-28 2013-11-14 Procédé pour indiquer la présence de tumeurs bénignes à l'aide d'un échantillon de cellules mononucléaires périphériques (pbmc)

Country Status (4)

Country Link
US (3) US9804145B2 (fr)
EP (2) EP3004870B1 (fr)
ES (1) ES2877332T3 (fr)
WO (1) WO2014191980A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533960A (ja) 2010-06-01 2013-08-29 トドス メディカル リミテッド がんの診断
US9719937B2 (en) 2011-05-11 2017-08-01 Todos Medical Ltd. Diagnosis of cancer
EP3004870B1 (fr) 2013-05-28 2019-01-02 Todos Medical Ltd. Diagnostic différentiel de tumeurs bénignes
WO2015009970A1 (fr) 2013-07-18 2015-01-22 Erythron Llc Mesures spectroscopiques avec un détecteur de réseaux parallèles
US10149620B2 (en) * 2013-12-23 2018-12-11 The University Of North Carolina At Charlotte Methods and systems using LED sources to create contrast agents for mid-infrared imaging of blood vessels
WO2015131151A2 (fr) 2014-02-28 2015-09-03 Erythron, Llc Méthode et appareil de détermination de marqueurs de santé par analyse d'un échantillon de sang
WO2016168090A1 (fr) 2015-04-14 2016-10-20 Nueon, Inc. Méthode et appareil pour déterminer des marqueurs de santé par analyse de sang
GB2537875A (en) * 2015-04-29 2016-11-02 Imp Innovations Ltd Infrared imaging of biological material
WO2017165403A1 (fr) 2016-03-21 2017-09-28 Nueon Inc. Procédés et appareil de spectrométrie à maillage poreux
WO2018085699A1 (fr) 2016-11-04 2018-05-11 Nueon Inc. Lancette et analyseur de sang combinés
EP3602011A2 (fr) 2017-03-31 2020-02-05 University of Strathclyde Système de spectroscopie infrarouge

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014134A1 (fr) * 1991-02-04 1992-08-20 National Research Council Of Canada Procede permettant de detecter la presence d'anomalies dans des cellules exfoliees par spectroscopie a infrarouge
AU2730095A (en) * 1994-06-28 1996-01-25 Patrick T.T. Wong Infrared spectroscopy of a sample treated with preservative
US5945674A (en) * 1997-07-30 1999-08-31 Vysis, Inc. Method of identifying cellular types in a biological sample supported on an absorptive substrate by infrared spectroscopy
US20020027649A1 (en) * 2000-07-08 2002-03-07 Victor Chudner Method for blood infrared spectroscopy diagnosing of inner organs pathology
US20020164810A1 (en) * 2000-12-05 2002-11-07 Vysis Method and system for diagnosing pathology in biological samples by detection of infrared spectral markers
WO2011121588A1 (fr) * 2010-03-29 2011-10-06 Ben Gurion University Of The Negev Research And Development Authority Procédé et système de détection et de surveillance d'un cancer hématologique

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912050A (en) 1986-02-26 1990-03-27 The Beth Israel Hospital Association Process for the screening of cancer using nuclear magnetic resonance
US4832483A (en) 1987-09-03 1989-05-23 New England Medical Center Hospitals, Inc. Method of using resonance raman spectroscopy for detection of malignancy disease
US5197470A (en) 1990-07-16 1993-03-30 Eastman Kodak Company Near infrared diagnostic method and instrument
US5168162A (en) * 1991-02-04 1992-12-01 Cornell Research Foundation, Inc. Method of detecting the presence of anomalies in exfoliated cells using infrared spectroscopy
US5261410A (en) * 1991-02-07 1993-11-16 Alfano Robert R Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy
DE69231614T2 (de) 1991-02-26 2001-05-03 Massachusetts Institute Of Technology, Cambridge Molekularspektroskopieverfahren und -einrichtungen zur gewebediagnose
EP0644412A3 (fr) 1993-09-17 1995-08-09 Boehringer Mannheim Gmbh Procédé pour l'analyse des liquides et des suspensions ayant un intéret clinique.
US5697373A (en) 1995-03-14 1997-12-16 Board Of Regents, The University Of Texas System Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies
US5733739A (en) 1995-06-07 1998-03-31 Inphocyte, Inc. System and method for diagnosis of disease by infrared analysis of human tissues and cells
US5766549A (en) * 1995-11-14 1998-06-16 Coulter International Corp. Apparatus for drying blood smear slides
AUPN825796A0 (en) 1996-02-26 1996-03-14 Ashdown, Martin The application of infrared (ir) spectrometry to the investigations of components of blood and other body fluids
US5945675A (en) 1996-03-18 1999-08-31 Pacific Northwest Research Foundation Methods of screening for a tumor or tumor progression to the metastatic state
AU8172998A (en) 1997-06-27 1999-01-19 Pacific Northwest Research Institute Methods of differentiating metastatic and non-metastatic tumors
US6274871B1 (en) 1998-10-22 2001-08-14 Vysis, Inc. Method and system for performing infrared study on a biological sample
US6251616B1 (en) 1999-01-14 2001-06-26 Biocrystal Ltd. Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response
US7450229B2 (en) 1999-01-25 2008-11-11 Amnis Corporation Methods for analyzing inter-cellular phenomena
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7524681B2 (en) 2001-01-22 2009-04-28 Andreas Wolf Rapid assay for biological substances using FTIR
IL146521A0 (en) 2001-11-15 2002-07-25 Univ Ben Gurion Novel optical method for diagnosis and grading of premalignant and malignant human colonic tissues
US8263664B2 (en) 2002-05-19 2012-09-11 University Of Utah Research Foundation pH-sensitive polymeric micelles for drug delivery
US7257437B2 (en) * 2002-07-05 2007-08-14 The Regents Of The University Of California Autofluorescence detection and imaging of bladder cancer realized through a cystoscope
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
AU2004235395A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
WO2006011487A1 (fr) 2004-07-30 2006-02-02 National University Corporation Chiba University Procede servant a mesurer la concentration du glucose dans le sang en utilisant la spectroscopie infrarouge et instrument employant celui-ci
KR20070043868A (ko) * 2004-08-02 2007-04-25 칠드런'즈 메디컬 센터 코포레이션 암에 대한 혈소판 바이오마커
US20070003921A1 (en) 2005-07-01 2007-01-04 Andrus Paul G Method of grading disease by Fourier Transform Infrared Spectroscopy
US20090175819A1 (en) 2005-11-15 2009-07-09 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
US20070161922A1 (en) * 2006-01-09 2007-07-12 Medical Optical Imaging Systems Ltd. Method of infrared tomography, active and passive, for earlier diagnosis of breast cancer
US8774902B2 (en) * 2006-06-01 2014-07-08 Passive Imaging Medical Systems Engineering Ltd. (Pims) Method of infrared thermography for earlier diagnosis of gastric colorectal and cervical cancer
JP5047962B2 (ja) 2006-07-06 2012-10-10 株式会社疲労科学研究所 近赤外光を用いたガン、全身性エリテマトーデス（ｓｌｅ）又は抗リン脂質抗体症候群に関する検査・診断装置の作動方法
US20100185064A1 (en) 2007-01-05 2010-07-22 Jadran Bandic Skin analysis methods
EP2220505B1 (fr) 2007-12-10 2015-10-28 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Procédés de diagnostic du cancer
RU2011102743A (ru) 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
US20100210023A1 (en) 2008-09-22 2010-08-19 The Regents Of The University Of California Salivary metabolic biomarkers for human oral cancer detection
AU2009313985B2 (en) * 2008-11-12 2014-07-31 Ventana Medical Systems, Inc. Methods and apparatuses for heating slides carrying specimens
JP2013533960A (ja) 2010-06-01 2013-08-29 トドス メディカル リミテッド がんの診断
SG179311A1 (en) * 2010-09-22 2012-04-27 Univ Singapore Methods and apparatus relating to integrated nir fluorescence and reflectance imaging and spectroscopy with polarization for improving tissue diagnosis and characterization
US9719937B2 (en) 2011-05-11 2017-08-01 Todos Medical Ltd. Diagnosis of cancer
US20140087397A1 (en) 2012-09-25 2014-03-27 Children's Hospital Medical Center Biomarkers for fanconi anemia
US9891108B2 (en) * 2012-10-03 2018-02-13 The Research Foundation For The State University Of New York Spectroscopic method for Alzheimer's disease diagnosis
EP3004870B1 (fr) 2013-05-28 2019-01-02 Todos Medical Ltd. Diagnostic différentiel de tumeurs bénignes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014134A1 (fr) * 1991-02-04 1992-08-20 National Research Council Of Canada Procede permettant de detecter la presence d'anomalies dans des cellules exfoliees par spectroscopie a infrarouge
AU2730095A (en) * 1994-06-28 1996-01-25 Patrick T.T. Wong Infrared spectroscopy of a sample treated with preservative
US5945674A (en) * 1997-07-30 1999-08-31 Vysis, Inc. Method of identifying cellular types in a biological sample supported on an absorptive substrate by infrared spectroscopy
US20020027649A1 (en) * 2000-07-08 2002-03-07 Victor Chudner Method for blood infrared spectroscopy diagnosing of inner organs pathology
US20020164810A1 (en) * 2000-12-05 2002-11-07 Vysis Method and system for diagnosing pathology in biological samples by detection of infrared spectral markers
WO2011121588A1 (fr) * 2010-03-29 2011-10-06 Ben Gurion University Of The Negev Research And Development Authority Procédé et système de détection et de surveillance d'un cancer hématologique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELA OSTROVSKY ET AL: "Detection of Cancer Using Advanced Computerized Analysis of Infrared Spectra of Peripheral Blood", IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, IEEE SERVICE CENTER, PISCATAWAY, NJ, USA, vol. 60, no. 2, 1 February 2013 (2013-02-01), pages 343 - 353, XP011487358, ISSN: 0018-9294, DOI: 10.1109/TBME.2012.2226882 *
M. KHANMOHAMMADI ET AL: "Chemometrics assisted investigation of variations in infrared spectra of blood samples obtained from women with breast cancer: a new approach for cancer diagnosis", EUROPEAN JOURNAL OF CANCER CARE, vol. 19, no. 3, 1 May 2010 (2010-05-01), pages 352 - 359, XP055143919, ISSN: 0961-5423, DOI: 10.1111/j.1365-2354.2008.01062.x *
See also references of WO2014191980A1 *
SYLWIA OLSZTYNSKA-JANUS ET AL: "Spectroscopic techniques in the study of human tissues and their components. Part I: IR spectroscopy", ACTA OF BIOENGINEERING AND BIOMECHANICS REVIEW ARTICLE, vol. 14, 1 January 2012 (2012-01-01), XP055177752, DOI: 10.5277/abb120314 *
UDI ZELIG ET AL: "Pre-screening and follow-up of childhood acute leukemia using biochemical infrared analysis of peripheral blood mononuclear cells", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, ELSEVIER, AMSTERDAM, NL, vol. 1810, no. 9, 15 June 2011 (2011-06-15), pages 827 - 835, XP028243467, ISSN: 0304-4165, [retrieved on 20110623], DOI: 10.1016/J.BBAGEN.2011.06.010 *

Also Published As

Publication number Publication date
EP3004870A1 (fr) 2016-04-13
EP3489659A1 (fr) 2019-05-29
US20180196028A1 (en) 2018-07-12
EP3004870B1 (fr) 2019-01-02
WO2014191980A1 (fr) 2014-12-04
US9804145B2 (en) 2017-10-31
US20160153958A1 (en) 2016-06-02
US11513112B2 (en) 2022-11-29
US20200355669A1 (en) 2020-11-12
EP3489659B1 (fr) 2021-03-03
ES2877332T3 (es) 2021-11-16
US10732165B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
EP3004870A4 (fr) Diagnostic différentiel de tumeurs bénignes
EP3027192A4 (fr) Méthodes permettant de traiter des tumeurs solides
EP3080613A4 (fr) Diagnostic différentiel de maladie du foie
EP3017759A4 (fr) Instrument médical
EP2967354A4 (fr) Évaluation pharmaco-diagnostique multimodale de la santé cérébrale
EP3047786A4 (fr) Endoscope
EP3033079A4 (fr) Méthodes de traitement d'un cancer amplifié par her2
EP3046583A4 (fr) Conjugués de pseudo-particules virales destinés au diagnostic et au traitement de tumeurs
EP2959823A4 (fr) Endoscope
EP3021866A4 (fr) Utilisations médicales d'agonistes de cd38
EP3041569A4 (fr) Détection de zones cardiaques souffrant d'un déficit de régulation
EP3042601A4 (fr) Partie de courbe d'endoscope
EP3009062A4 (fr) Endoscope
EP3084006A4 (fr) Réduction de la diaphonie
EP2988659A4 (fr) Procédés améliorés de détection du cancer
EP3055281A4 (fr) Préparation de dérivés d'hydroxy-benzylbenzène
EP3066625A4 (fr) Carte d'assurance-maladie à double fonction
EP2996721A4 (fr) Méthodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8
EP3017747A4 (fr) Endoscope
EP3008212A4 (fr) Méthodes de traitement du cancer
EP3087898A4 (fr) Endoscope
EP3075298A4 (fr) Endoscope
EP3062790A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3000378A4 (fr) Endoscope
EP2989961A4 (fr) Endoscope

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/00 20060101ALI20170119BHEP

Ipc: G01N 33/487 20060101ALI20170119BHEP

Ipc: G01N 21/3577 20140101ALI20170119BHEP

Ipc: G01N 21/359 20140101AFI20170119BHEP

Ipc: G01N 21/3563 20140101ALI20170119BHEP

Ipc: G01N 21/35 20140101ALI20170119BHEP

Ipc: G01N 33/48 20060101ALI20170119BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170126

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013049402

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G01N0033480000

Ipc: G01N0021359000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/487 20060101ALI20180614BHEP

Ipc: G01N 21/3563 20140101ALI20180614BHEP

Ipc: G01N 33/483 20060101ALI20180614BHEP

Ipc: G01N 33/48 20060101ALI20180614BHEP

Ipc: G01N 21/3577 20140101ALI20180614BHEP

Ipc: G01N 21/35 20140101ALI20180614BHEP

Ipc: G01N 21/359 20140101AFI20180614BHEP

Ipc: A61B 5/00 20060101ALI20180614BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180719

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1085021

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013049402

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1085021

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190402

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190502

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190402

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190502

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013049402

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

26N No opposition filed

Effective date: 20191003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191114

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131114

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20211115

Year of fee payment: 9

Ref country code: DE

Payment date: 20211116

Year of fee payment: 9

Ref country code: FR

Payment date: 20211125

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20211203

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013049402

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221114

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130